A
Andreessen Horowitz LLC
+ HoldingBRVE
-2.12%
3M Return
$18.710
-0.805 (-4.30%)At close
Loading chart…
- High
- 19.588
- Open
- 19.500
- VWAP
- 18.77
- Volume
- 414.87K
- Mkt Cap
- —
- Low
- 18.000
- Amount
- 7.79M
- EV/EBITDA, TTM
- 0.00
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.
AI analysis of Braveheart Bio, Inc. (BRVE)
SellBraveheart Bio, Inc. is not a good buy right now due to significant financial losses and negative price momentum. The current price is $18.71, with a recent 5-day change of -6.54% and a year-to-date change of only +3.94%. The company's net loss for Q2 2026 was $18.60 million, up from $0.38 million the previous year, indicating worsening financial health. Additionally, the RSI is at 32.844, suggesting the stock is oversold, but this may not be enough to justify a buy given the ongoing losses and high clinical development costs.
Valuation Metrics
The current forward P/E ratio for Braveheart Bio, Inc. (BRVE) is 0.00, compared to its 5-year average forward P/E of .
Whales holding BRVE
Events Timeline
News
9.509-09NASDAQ.COMBraveheart Bio Reports Wider Q2 Loss Amid Clinical Advancements
8.509-01renaissancecapitalSix IPOs and Five SPACs Priced This Week
- 8.509-01renaissancecapital
IPO and SPAC Market Dynamics This Week
8.509-01renaissancecapitalAugust IPO Market Review and Outlook
8.509-01renaissancecapitalAugust IPO Market Review and Outlook
BRVE FAQ — answered by Alphio AI
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart. It operates in the Healthcare sector.
Braveheart Bio, Inc. is not a good buy right now due to significant financial losses and negative price momentum. The current price is $18.71, with a recent 5-day change of -6.54% and a year-to-date change of only +3.94%. The company's net loss for Q2 2026 was $18.60 million, up from $0.38 million the previous year, indicating worsening financial health. Additionally, the RSI is at 32.844, suggesting the stock is oversold, but this may not be enough to justify a buy given the ongoing losses and high clinical development costs.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.